2022
DOI: 10.11569/wcjd.v30.i16.735
|View full text |Cite
|
Sign up to set email alerts
|

Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 60 publications
0
1
0
Order By: Relevance
“…Inflammation-induced inactivation of mitotic fusion 2 activity may impair mitophagy through related pathways, reduce autophagosome formation, and exacerbate hepatic steatosis, leading to the progression of NASH. Activation of mitochondrial enzymes such as peroxisome proliferatoractivated receptor α (PPARα) by specific agonists can significantly increase lipid metabolism and inhibit hepatic steatosis via the miR-21 pathway [40,41].…”
Section: Mitochondrionmentioning
confidence: 99%
“…Inflammation-induced inactivation of mitotic fusion 2 activity may impair mitophagy through related pathways, reduce autophagosome formation, and exacerbate hepatic steatosis, leading to the progression of NASH. Activation of mitochondrial enzymes such as peroxisome proliferatoractivated receptor α (PPARα) by specific agonists can significantly increase lipid metabolism and inhibit hepatic steatosis via the miR-21 pathway [40,41].…”
Section: Mitochondrionmentioning
confidence: 99%